Alta Partners http://www.altapartners.com/ Alta Partners news. en Copyright 2006 Tue, 27 Jul 2010 00:00:00 +0800 http://www.php.net/ http://blogs.law.harvard.edu/tech/rss <![CDATA[Immune Design To Advance Vaccines Pipeline With $32M Series B]]> Source: VentureWire Lifescience

By Brian Gormley
7/27/2010 - Seattle -

Immune Design Corp. has raised a $32 million Series B round to advance its initial vaccines for cancer and infectious disease into clinical trials next year.

New investor ProQuest Investments led the round and was joined by all previous backers: Alta Partners, Column Group and Versant Ventures. The Seattle-based company has now raised a total of $50 million since forming in 2008. Valuation was not ... ]]> http://www.altapartners.com/news_detail.php?id=498 http://www.altapartners.com/news_detail.php?id=498 Tue, 27 Jul 2010 00:00:00 +0800 <![CDATA[Cerenis Therapeutics Hauls In $51M For HDL Drug Trials]]> Source: VentureWire Lifescience

By Brian Gormley
7/26/2010 - Toulouse, France -

Venture firms are funneling EUR40 million ($51 million) into a company with a drug that could remove cholesterol from hardening arteries.

The financing for Cerenis Therapeutics SA is the first closing of a Series C round of undisclosed size. The funding will enable Cerenis to test the drug's ability to reduce artery plaque in a Phase II study of patients at high risk for a heart attack.

http://www.altapartners.com/news_detail.php?id=497 http://www.altapartners.com/news_detail.php?id=497 Mon, 26 Jul 2010 00:00:00 +0800 <![CDATA[Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™]]> Source: Kiadis Pharma website

http://kiadis.com/news/item/kiadis_pharma_receives_ind_approval_from_fda_to_start_pivotal_clinical_trial_with_atir_/62

]]> http://kiadis.com/news/item/kiadis_pharma_receives_ind_approval_from_fda_to_start_pivotal_clinical_trial_with_atir_/62 http://kiadis.com/news/item/kiadis_pharma_receives_ind_approval_from_fda_to_start_pivotal_clinical_trial_with_atir_/62 Tue, 20 Jul 2010 00:00:00 +0800 <![CDATA[Trevena Secures $35 Million in Series B Funding]]> Source: Trevena website

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing. Proceeds will be used to ... ]]> http://www.altapartners.com/news_detail.php?id=495 http://www.altapartners.com/news_detail.php?id=495 Wed, 14 Jul 2010 00:00:00 +0800 <![CDATA[Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Hemophilia B Therapy at the World Federation of Hemophilia Congress]]> Source: Biovitrum Website

http://hugin.info/134557/R/1430956/377500.pdf

]]> http://hugin.info/134557/R/1430956/377500.pdf http://hugin.info/134557/R/1430956/377500.pdf Mon, 12 Jul 2010 00:00:00 +0800